Notícias e Atividades da Frazier Life Sciences

A Frazier Life Sciences pertence à Frazier Healthcare Partners.

Frazier Healthcare Partners possui 9 subsidiárias incluindo AirNexis Therapeutics, Altruix e Comprehensive Pharmacy Services.

Eles estão dentro:

• Saúde30%
• Fundo20%
• Outro50%

Fusão, aquisição e financiamento envolvendo Frazier Healthcare Partners.

• Frazier Healthcare Partners adquiriu Altruix (publicado em 29 de maio de 2026).

Veja o organograma con seus 43 executivos principais

Biografias mais buscadas da Frazier Life Sciences

• Albert Cha, Managing Partner
• Patrick Heron, Managing Partner
• James Topper, Managing Partner

Recentes movimentos de executivos em Frazier Life Sciences

• Mansi Shinde, ingressou na Companhia como Vice President of Company Creation  (Notícia publicada em 22 de março de 2026).
• Kiah Williams antes Senior Associate, foi promovido a Vice President  (Notícia publicada em 13 de janeiro de 2026).
• Angel Martin antes Senior Associate, foi promovido a Vice President  (Notícia publicada em 13 de janeiro de 2026).

Clique aqui para ver outras movimentos em Frazier Life Sciences

Criar um alerta
para seguir os movimentos de executivos da Frazier Life Sciences.

Frazier Healthcare Partners possui 1.642 concorrentes concorrentes Griffin Gaming Partners (Estados Unidos), BlackRock (Estados Unidos) e KKR (Estados Unidos).

Popular M&A news in Fundo

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (publicado em 3 de junho de 2026).
• Prime Capital Financial adquiriu Access Capital Partners (publicado em 2 de junho de 2026).
• Frazier Healthcare Partners adquiriu Altruix (publicado em 29 de maio de 2026).

Outros contatos sugeridos na indústria do Fundo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director da Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director da KKR

Saiba mais sobre a indústria do Fundo

Últimos comunicados de imprensa de Frazier Life Sciences

• GSK enters agreement to acquire 35Pharma Inc. | GSK
• Page not found
• Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer
• Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
• Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
• Frazier Life Sciences Appoints Charles Fuchs as Senior Advisor
• Frazier Life Sciences Announces Multiple Promotions to Key Senior Level Positions
• Tubulis raises €308M to advance ADC development · Tubulis News
• Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
• KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema | KalVista Pharmaceuticals
• View more press releases Close

Redes sociais sobre Frazier Life Sciences

• Frazier Life Sciences na Wikipedia, Google News e Yahoo Finance
• Frazier Life Sciences na LinkedIn, X (Twitter) e YouTube